Syros
Dec 19, 2019
GBT, Syros; Takeda, Cevance collaborates; IND application to ZN-c3
Global Therapeutics and Syros Pharmaceuticals have teamed up to move forward to discover, develop and market novel Sickle cell disease and beta-thalassemia therapies. Inherited blood disorders affect millions of people worldwide. As per NIH, Sickle cell disease affects around 70,000 to 80,000 Americans, wh...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
